Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00400426
Status:
COMPLETED
Last Update Posted:
2013-06-19
First Post:
2006-11-15
Brief Title:
DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer
Sponsor:
University of Aarhus
Organization:
University of Aarhus
Study Overview
Official Title:
DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Palliative radiotherapy for head and neck cancer is widely used but the effect and side effects are largely unknown We will study the effect of short hypofractionated palliative radiotherapy 20 Gy in 4 fractions on symptom intensity and -frequency as weel as side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None